Sandoz Group AG (D8Y.F)
Frankfurt · EUR · Healthcare · Drug Manufacturers - Specialty & Generic
€88.50 (-0.76%) as of
Key statistics
- Market cap
- 38.29B
- P/E (TTM)
- 68.08
- EPS (TTM)
- 1.30
- Dividend yield
- 1.00%
- 52-week range
- 53.50 – 89.20
- Beta
- 0.46
- Revenue (TTM)
- 11.68B
- Profit margin
- 5.53%
- Volume
- 773.00
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Basel, Switzerland
- Employees
- 20,000
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.